---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000070"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:39:40.193676+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals reports Q1 net loss of $1.9M; positive clinical data for KIO-301, KIO-201, KIO-101

## Summary
- Net loss narrowed to $1.9M from $3.6M in Q1 2022; cash & equivalents $3.4M plus $1.7M R&D tax receivables.
- KIO-301 (ABACUS trial) showed profound light perception improvements in a blind RP patient; full results by end 2023.
- KIO-201 Phase 2 PCED trial met primary endpoint in 5 of 8 patients at 4 weeks; planning registration study.
- KIO-101 Phase 2 OPRA trial first patient enrolled in April; targeting ocular surface disease from autoimmune conditions.
- Approximately $9.6M available under equity line of credit; R&D expenses fell to $0.4M from $0.7M.

## SEC filing metadata
- accession: 0001372514-23-000070
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000070/0001372514-23-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000070/kprx-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000070
- JSON: https://secwatch.observer/filing/0001372514-23-000070.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000070.txt

## Key facts
- Earnings Releases
  KIORA PHARMACEUTICALS INC reported first quarter ended March 31, 2023 results: net income $1.9 million.
  - Period: first quarter ended March 31, 2023
  - Net income: $1.9 million
  - Result: reported results
  source text: Net loss was $1.9 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000070/0001372514-23-000070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.